Revenue Recognition - Narrative (Details) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Jul. 31, 2020 USD ($)	Sep. 30, 2020 USD ($)	Sep. 30, 2019 USD ($)	Sep. 30, 2020 USD ($)	Sep. 30, 2019 USD ($)	Dec. 31, 2019 USD ($)
Disaggregation of Revenue [Line Items]
Revenues		$ 93,106	$ 83,808	$ 210,637	$ 237,062
Current portion of deferred revenue		2,477		2,477		$ 0
Norgine B.V. | Ciraparantag
Disaggregation of Revenue [Line Items]
Proceeds related to collaborative arrangement	$ 30,000
Recovery of direct costs	33.00%
Potential milestone proceeds from collaborative arrangement payable to equity holders	$ 40,000
Incurred contract acquisition costs		2,000		2,000
Incurred contract acquisition costs amortized				1,300
Incurred contract acquisition costs deferred		700		700
Norgine B.V. | Ciraparantag | Maximum | Regulatory Milestone Achievement
Disaggregation of Revenue [Line Items]
Potential milestone proceeds from collaborative arrangement	70,000
Norgine B.V. | Ciraparantag | Maximum | Sales Milestones Achievement
Disaggregation of Revenue [Line Items]
Potential milestone proceeds from collaborative arrangement	190,000
Norgine B.V. | License Rights
Disaggregation of Revenue [Line Items]
Revenues	$ 19,800
Norgine B.V. | License Rights | Valuation Technique, Discounted Cash Flow | Measurement Input, Discount Rate
Disaggregation of Revenue [Line Items]
Revenue, performance obligation, measurement input	0.27
Norgine B.V. | Research And Development Services
Disaggregation of Revenue [Line Items]
Revenues, remaining performance obligation, amount	$ 10,200
Norgine B.V. | Development Services
Disaggregation of Revenue [Line Items]
Deferred revenue		10,200		10,200
Current portion of deferred revenue		$ 2,500		$ 2,500